A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Sponsor

Centocor, Inc. (Industry)

Overall Status

Terminated

CT.gov ID

NCT00073372

Collaborator

Eli Lilly and Company (Industry)

808

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.

Condition or Disease	Intervention/Treatment	Phase
Cerebrovascular Accident Brain Ischemia Acute Disease	Drug: Abciximab	Phase 3

Detailed Description

Abciximab is a drug that prevents platelets from sticking together and forming a clot. There are limited studies using abciximab in the treatment of strokes. This phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study is designed to assess the effectiveness and safety of abciximab for treatment of acute ischemic stroke, in helping dissolve clots in brain arteries so that blood and oxygen can flow better and there may be less brain damage.

Safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. Patients will receive either Abciximab: 0.25 mg/kg bolus (to a maximum of 30 mg) followed by a 0.125 µg/kg/min infusion (to a maximum of 10 µg/min) for 12 hours or a bolus of placebo followed by infusion for 12 hours

Study Design

Study Type:

Interventional

Actual Enrollment :

808 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

Study Start Date :

Oct 1, 2003

Actual Study Completion Date :

Dec 1, 2005

Outcome Measures

Primary Outcome Measures

The proportion of modified Rankin Scale responders at 3 months in the primary population. []

Secondary Outcome Measures

Proportion of patients with neurological recovery and all-cause mortality at 3 months in the primary population. Fatal intracranial-, nonfatal symptomatic parenchymal-, or other symptomatic intracranial hemorrhages though discharge at day 5 & 3 months []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with diagnosis of acute ischemic stroke with onset within 5 hours and 30 minutes before randomization and planned treatment initiation within 6 hours of onset
After 600 patients are enrolled in previous criteria, the new criteria for enrollment will be, patients with diagnosis of acute ischemic stroke with onset within 4 hours and 30 minutes before randomization and planned treatment initiation within 5 hours of onset

Exclusion Criteria:

Patients who had participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial
Patients with symptoms suggestive of subarachnoid hemorrhage
Female patients known to be pregnant, lactating, or having a positive or indeterminate pregnancy test
Patients with neurological deficit that has led to stupor or coma
Patients with minor stroke